Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
SHANGHAI PECHEM
00338
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Special items of operating revenue | 44.83%9.72B | 16.07%34.99B | 20.55%23.07B | 14.19%16.28B | 5.85%6.71B | -11.30%30.14B | -22.37%19.14B | -23.56%14.26B | -27.74%6.34B | -6.83%33.98B |
| Operating income | 44.83%9.72B | 16.07%34.99B | 20.55%23.07B | 14.19%16.28B | 5.85%6.71B | -11.30%30.14B | -22.37%19.14B | -23.56%14.26B | -27.74%6.34B | -6.83%33.98B |
| Operating expenses | ||||||||||
| Gross profit | ||||||||||
| Administrative expenses | -25.25%-3.04B | ---- | -4.42%-8.05B | ---- | 5.35%-2.43B | ---- | 8.99%-7.71B | ---- | 8.48%-2.57B | ---- |
| Employee expense | ---- | -11.66%-7.04B | ---- | 7.57%-3.3B | ---- | 20.87%-6.31B | ---- | 12.30%-3.58B | ---- | -1.03%-7.97B |
| Impairment and provision | 128.88%52.31M | -177.63%-303.12M | -262.05%-186.09M | 2.44%-97.88M | -589.55%-181.16M | -189.55%-109.18M | 551.69%114.84M | -804.31%-100.33M | 202.37%37M | 139.23%121.93M |
| -Other impairment is provision | 128.88%52.31M | -177.63%-303.12M | -262.05%-186.09M | 2.44%-97.88M | -589.55%-181.16M | -189.55%-109.18M | 551.69%114.84M | -804.31%-100.33M | 202.37%37M | 139.23%121.93M |
| Operating interest expense | -2.86%-2.03B | 1.72%-7.76B | 3.06%-5.79B | 2.37%-3.89B | 3.76%-1.97B | 6.06%-7.9B | 4.87%-5.97B | 3.60%-3.98B | 1.38%-2.05B | -17.70%-8.41B |
| Special items of operating profit | -6.10%-549.9K | -13.64%-7.98B | 33.31%-421.38M | -7.10%-3.6B | 99.88%-518.28K | 23.90%-7.02B | 69.17%-631.83M | 35.43%-3.37B | 47.66%-419.73M | 19.84%-9.23B |
| Operating profit | 121.89%4.67B | 35.15%11.73B | 74.98%8.53B | 67.13%5.32B | 58.91%2.1B | 3.80%8.68B | -37.30%4.87B | -38.40%3.18B | -56.20%1.32B | -11.57%8.36B |
| Share of profits of associates | ---- | -60.77%3.26M | ---- | -73.28%1.66M | ---- | 12.82%8.32M | ---- | 5,660.19%6.22M | ---- | -45.45%7.37M |
| Special items of earning before tax | -743.33%-3.61M | ---- | 67.44%-10.67M | ---- | 64.80%-428.64K | ---- | 96.70%-32.78M | ---- | 98.14%-1.22M | ---- |
| Earning before tax | 121.76%4.66B | 35.06%11.74B | 75.94%8.51B | 66.85%5.32B | 59.03%2.1B | 3.80%8.69B | -28.61%4.84B | -38.28%3.19B | -55.28%1.32B | -11.62%8.37B |
| Tax | ---- | -56.92%-2.28B | ---- | -146.53%-807.94M | ---- | -9.84%-1.45B | ---- | 61.66%-327.72M | ---- | 31.82%-1.32B |
| After-tax profit from continuing operations | 98.76%3.67B | 30.66%9.45B | 64.88%7.1B | 57.73%4.52B | 50.01%1.85B | 2.67%7.24B | -24.49%4.31B | -33.65%2.86B | -49.33%1.23B | -6.40%7.05B |
| Earning after tax | 98.76%3.67B | 30.66%9.45B | 64.88%7.1B | 57.73%4.52B | 50.01%1.85B | 2.67%7.24B | -24.49%4.31B | -33.65%2.86B | -49.33%1.23B | -6.40%7.05B |
| Minority profit | -32.27%2.53M | 18.61%14.6M | 26.04%10.56M | 38.73%7.54M | 25.55%3.74M | -4.29%12.31M | -24.52%8.38M | -28.18%5.43M | -0.63%2.98M | 26.65%12.86M |
| Profit attributable to shareholders | 99.03%3.67B | 30.68%9.44B | 64.95%7.09B | 57.77%4.51B | 50.07%1.84B | 2.68%7.22B | -24.49%4.3B | -33.66%2.86B | -49.39%1.23B | -6.45%7.03B |
| Basic earnings per share | 120.00%0.44 | 37.97%1.09 | 82.22%0.82 | 73.33%0.52 | 66.67%0.2 | 1.28%0.79 | -29.69%0.45 | -38.78%0.3 | -57.14%0.12 | -9.30%0.78 |
| Diluted earnings per share | 120.00%0.44 | 37.97%1.09 | 82.22%0.82 | 73.33%0.52 | 66.67%0.2 | 1.28%0.79 | -29.69%0.45 | -38.78%0.3 | -57.14%0.12 | -9.30%0.78 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.